首页> 外文期刊>International archives of allergy and immunology >Effect on cell surface markers following allergen-induced desensitization of human whole-blood basophils.
【24h】

Effect on cell surface markers following allergen-induced desensitization of human whole-blood basophils.

机译:变应原诱导人类全血嗜碱粒细胞脱敏后对细胞表面标志物的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Allergen-specific immunotherapy (SIT) leads to reduced symptoms upon allergen exposure through as yet unresolved mechanisms. Desensitization of basophils to specific allergens during the updosing phase of injection immunotherapy may contribute to the clinical effect of SIT. Here we report a protocol for efficient in vitro allergen-mediated desensitization of basophils in whole blood and the effect of desensitization on the expression of basophil activation markers (CD203c and CD63) as well as histamine release in response to allergen challenge. METHODS: Whole blood from grass pollen-allergic subjects was incubated with Phleum pratense extract by stepwise increase of the allergen concentration in the culture from well below to well above the allergen threshold concentration for activation of basophils. Desensitization was determined by measuring the expression of the basophil activation markers CD63 and CD203c by FACS following challenge with high allergen concentrations. RESULTS: The basophil desensitization protocol reported here affected both the expression of the cell-surface markers and the levels of histamine release. Following the stepwise desensitization procedure the whole-blood basophils were not activated when challenged with more than 10-fold increased allergen concentration. CONCLUSION: We have established a protocol for basophil desensitization. By mimicking the updosing phase of immunotherapy we raised the allergen threshold for basophil activation and obtained efficient desensitization for all donors. We showed that conditions leading to desensitization affect histamine release and expression of different basophil markers alike.
机译:背景:过敏原特异性免疫疗法(SIT)可通过尚未解决的机制降低过敏原暴露后的症状。在注射免疫治疗的剂量加大阶段,嗜碱性粒细胞对特定过敏原的脱敏可能有助于SIT的临床效果。在这里,我们报告了有效的全血中嗜碱性粒细胞体外变应原介导的脱敏以及脱敏对嗜碱性粒细胞活化标志物(CD203c和CD63)的表达以及对过敏原激发的组胺释放的影响的协议。方法:通过将培养物中的变应原浓度从远低于敏变的阈值浓度逐步增加到远高于远高于激活嗜碱细胞的变应原浓度,将草花粉过敏受试者的全血与incubated草提取物一起孵育。在高过敏原浓度激发后,通过FACS测量嗜碱性粒细胞活化标记CD63和CD203c的表达来确定脱敏。结果:此处报道的嗜碱性粒细胞脱敏方案影响细胞表面标志物的表达和组胺释放的水平。按照逐步脱敏步骤进行,当变应原浓度增加超过10倍时,全血嗜碱性粒细胞不会被激活。结论:我们已经建立了嗜碱性粒细胞脱敏的方案。通过模仿免疫疗法的剂量加大阶段,我们提高了嗜碱性粒细胞激活的过敏原阈值,并为所有供体获得了有效的脱敏作用。我们表明导致脱敏的条件会影响组胺的释放和不同嗜碱性粒细胞标志物的表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号